Article

ACR Appropriateness Criteria (R) Pretreatment Staging of Colorectal Cancer

Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Journal of the American College of Radiology: JACR (Impact Factor: 2.28). 11/2012; 9(11):775-81. DOI: 10.1016/j.jacr.2012.07.025
Source: PubMed

ABSTRACT Because virtually all patients with colonic cancer will undergo some form of surgical therapy, the role of preoperative imaging is directed at determining the presence or absence of synchronous carcinomas or adenomas and local or distant metastases. In contrast, preoperative staging for rectal carcinoma has significant therapeutic implications and will direct the use of radiation therapy, surgical excision, or chemotherapy. CT of the chest, abdomen, and pelvis is recommended for the initial evaluation for the preoperative assessment of patients with colorectal carcinoma. Although the overall accuracy of CT varies directly with the stage of colorectal carcinoma, CT can accurately assess the presence of metastatic disease. MRI using endorectal coils can accurately assess the depth of bowel wall penetration of rectal carcinomas. Phased-array coils provide additional information about lymph node involvement. Adding diffusion-weighted imaging to conventional MRI yields better diagnostic accuracy than conventional MRI alone. Transrectal ultrasound can distinguish layers within the rectal wall and provides accurate assessment of the depth of tumor penetration and perirectal spread, and PET and PET/CT have been shown to alter therapy in almost one-third of patients with advanced primary rectal cancer. The ACR Appropriateness Criteria(®) are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

2 Followers
 · 
136 Views
  • Source
    • "Diagnosis of primary tumors relies on colonoscopy and biopsy. Thoracoabdominal contrast-enhanced computed tomography (CT) is recommended to assess the extent of the disease [4] [5]. Positron emission tomography (PET) with the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose (FDG) is widely used in cancer imaging, mostly in integrated PET/ CT systems. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Optimal management of colon cancer (CC) requires detailed assessment of extent of disease. This study prospectively investigates the diagnostic accuracy of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (PET/CT) for staging and detection of recurrence in primary CC. Material and methods PET/CT for preoperative staging was performed in 66 prospectively included patients with primary CC. Diagnostic accuracy for PET/CT and CT was analyzed. In addition to routine follow up, 42 stages I–III CC patients had postoperative PET/CT examinations every 6 months for 2 years. Serological levels of tissue inhibitor of metalloproteinase-1 (TIMP-1), carcinoembryonic antigen, and liberated domain I of urokinase plasminogen activator receptor were analyzed. Results Accuracy for tumor, nodal, and metastases staging by PET/CT were 82% (95% confidence interval [CI]: 70; 91), 66% (CI: 51; 78), and 89% (CI: 79; 96); for CT the accuracy was 77% (CI: 64; 87), 60% (CI: 46; 73), and 69% (CI: 57; 80). Cumulative relapse incidences for stages I–III CC at 6, 12, 18, and 24 months were 7.1% (CI: 0; 15); 14.3% (CI: 4; 25); 19% (CI: 7; 31), and 21.4% (CI: 9; 34). PET/CT diagnosed all relapses detected during the first 2 years. High preoperative TIMP-1 levels were associated with significant hazards toward risk of recurrence and shorter overall survival. Conclusions This study indicates PET/CT as a valuable tool for staging and follow up in CC. TIMP-1 provided prognostic information potentially useful in selection of patients for intensive follow up.
    Scandinavian Journal of Gastroenterology 11/2013; 49(2). DOI:10.3109/00365521.2013.863967 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rectal cancer treatment is a multidisciplinary process highly dependent on accurate clinical staging at diagnosis. Defining the height, local invasion, and nodal invasion of the primary tumor determines the extent and order of the treatment scheme, which combines both surgery and chemo–radiotherapy. This review discusses the means by which the clinical stage is determined and the advantages and disadvantages of the different modalities.
    Current Colorectal Cancer Reports 03/2013; 9(1). DOI:10.1007/s11888-012-0155-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography/magnetic resonance imaging (PET/MRI) leverages the high soft-tissue contrast and the functional sequences of MR with the molecular information of PET in one single, hybrid imaging technology. This technology, which was recently introduced into the clinical arena in a few medical centers worldwide, provides information about tumor biology and microenvironment. Studies on indirect PET/MRI (use of positron emission tomography/computed tomography (PET/CT) images software fused with MRI images) have already generated interesting preliminary data to pave the ground for potential applications of PET/MRI. These initial data convey that PET/MRI is promising in neuro-oncology and head & neck cancer applications as well as neoplasms in the abdomen and pelvis. The pediatric and young adult oncology population requiring frequent follow-up studies as well as pregnant woman might benefit from PET/MRI due to its lower ionizing radiation dose. The indication and planning of therapeutic interventions and specifically radiation therapy in individual patients could be and to a certain extent are already facilitated by performing PET/MRI. The objective of this article is to discuss potential clinical oncology indications of PET/MRI.
    American Journal of Nuclear Medicine and Molecular Imaging 01/2014; 4(2):202-212. · 3.25 Impact Factor
Show more